BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29545185)

  • 1. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis.
    Siyahian A; Malik SU; Mushtaq A; Howe CL; Majeed A; Zangeneh T; Iftikhar S; Habib S; Zahid U; Riaz IB; Warraich Z; Faridi W; Anwer F
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1483-1489. PubMed ID: 29545185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation.
    Zhang JW; Zhang XZ; Sun YL; Long B; Wang XZ; Li XD
    BMC Infect Dis; 2019 Jan; 19(1):57. PubMed ID: 30651070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area.
    Wu Y; Chen Y; Zhu P; Ye B; Lu Y; Shi J; Tan Y; Zhao Y; Yu J; Lai X; Lan J; Si T; Ni L; Huang H; Luo Y
    Ann Hematol; 2022 Mar; 101(3):631-641. PubMed ID: 34981143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review.
    Gentile G; Antonelli G
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31717647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience.
    Shang J; Wang H; Sun J; Fan Z; Huang F; Zhang Y; Jiang Q; Dai M; Xu N; Lin R; Liu Q
    Bone Marrow Transplant; 2016 Apr; 51(4):581-6. PubMed ID: 26752138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
    Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
    Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
    Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.
    Cerva C; Colagrossi L; Maffongelli G; Salpini R; Di Carlo D; Malagnino V; Battisti A; Ricciardi A; Pollicita M; Bianchi A; Picardi A; Cudillo L; Cerretti R; De Angelis G; Cantonetti M; Andreoni M; Perno CF; Arcese W; Svicher V; Sarmati L
    Clin Microbiol Infect; 2016 Nov; 22(11):946.e1-946.e8. PubMed ID: 27475741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.
    Milazzo L; Corbellino M; Foschi A; Micheli V; Dodero A; Mazzocchi A; Montefusco V; Zehender G; Antinori S
    Transpl Infect Dis; 2012 Feb; 14(1):95-8. PubMed ID: 21749588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
    Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.
    Cerva C; Maffongelli G; Svicher V; Salpini R; Colagrossi L; Battisti A; Mariotti B; Cerretti R; Cudillo L; Sarmati L
    BMC Infect Dis; 2017 Aug; 17(1):566. PubMed ID: 28806922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review.
    Gentile G; Andreoni M; Antonelli G; Sarmati L
    Clin Microbiol Infect; 2017 Dec; 23(12):916-923. PubMed ID: 28668465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A; Boehm S; Hahn J; Holler E; Jilg W
    J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation.
    Elsebaey MA; Elbedewy TA; Elashry H; Elrefaey W; Elshweikh SA; Elhadidy AA; Shalaby NA; Elsokkary AM; Elashtokhy HEA; Abo-Amer YE; Abo-Elfetoh AR; Hassanien SEA; Fouad A; Abdellatif RS; Ismail AAM
    Medicine (Baltimore); 2022 Nov; 101(47):e31962. PubMed ID: 36451458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: a pediatric experience.
    Faraci M; Cappelli B; Lanino E; Morreale G; Fioredda F; Giudice CL; Giacchino R
    Pediatr Transplant; 2009 Nov; 13(7):923-6. PubMed ID: 19032422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation.
    Henkes M; Martin S; Einsele H; Aulitzky WE
    Ann Hematol; 2002 Jun; 81(6):343-6. PubMed ID: 12107567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
    Yaşar DG; Suyanı E; Özenirler S; Sucak GT
    Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.